Kyverna Therapeutics (KYTX) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 20.0% versus a loss of 39.9%. X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $269.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | XFOR |
|---|---|---|
| Share price | $4.26 | $3.00 |
| Market cap | $269.33M | $306.34M |
| 1-day change | -2.52% | +1.35% |
| YTD return | -54.68% | -25.00% |
| 1-year return | -39.92% | -20.00% |
| 5-year return | — | -97.79% |
| P/E ratio (TTM) | — | 5.45 |
| EPS (TTM) | $-2.75 | $0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.50M |
| Revenue growth (YoY) | — | +150.00% |
| Net income (latest FY) | $-161.31M | $-79.20M |
| Gross margin | — | 11.43% |
| Operating margin | — | -1336.66% |
| Net margin | — | -1218.45% |
| 52-week high | $13.67 | $4.83 |
| 52-week low | $4.18 | $2.43 |
| Distance from 52-week high | -68.84% | -37.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +613.62% | +286.67% |
| Average volume | 867.28K | 877.70K |
| Shares outstanding | 63.22M | 102.11M |
| Employees | 172 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed KYTX by 19.9 percentage points over the past year.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
KYTX vs XFOR FAQ
Which is bigger, Kyverna Therapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $269.33M for Kyverna Therapeutics (KYTX).
Which stock has performed better over the past year, KYTX or XFOR?
XFOR returned -20.00% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Kyverna Therapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.